Novo Nordisk nudges up 2019 sales outlook as new drugs excel
Share:
COPENHAGEN (Reuters) - Novo Nordisk posted third-quarter operating profit a touch below expectations on Friday on weak insulin sales and impairments, but nudged up its sales outlook on hopes for new type 2 diabetes and obesity drugs.Novo now sees 2019 sales growth at 5-6% versus 4-6% previously, and held its forecast for operating profit growth at 4-6%, both in local currency terms. It said operating profit rose 9% in the last quarter, slightly below analysts' forecasts.Shares in the healthcare..